Introduction

Imagine your body's defence system, like a security team, accidentally attacking the area around your eyes. That's what happens in Thyroid Eye Disease (TED). It's like a friendly fire incident. Often, this occurs when the security team is already confused and attacking the thyroid gland in Graves' disease. But, sometimes, this 'friendly fire' happens even when the security team behaves normally.¹

Thyroid Eye Disease (TED) threatens eyesight by causing inflammation, swelling, and scarring of the tissues surrounding the eye. This leads to the eyes bulging outward (proptosis), double vision (diplopia), and, in severe instances, loss of vision.¹ Specifically, this article examines how the immune system drives TED, highlighting how autoantibodies, orbital fibroblasts, and inflammatory cytokines contribute to the disease's advancement.

Overview of thyroid eye disease (TED)

The body's immune system mistakenly targets orbital tissues in Thyroid Eye Disease (TED), an autoimmune disorder. Thyroid-stimulating hormone receptor (TSHR) autoantibodies cause Graves' disease, an autoimmune hyperthyroidism condition, and TED most commonly occurs in patients with Graves' disease ^{1 6}

TED affects approximately 25-50% of people who have Graves' disease. While women experience TED more frequently, men tend to develop more severe forms of the condition.⁸ Several factors increase the risk of developing TED, including an existing autoimmune predisposition, smoking, which both increases the risk and severity, uncontrolled thyroid dysfunction, genetic factors like HLA-DR3 and CTLA-4 mutations, and environmental triggers.^{1 3 5}

Thyroid Eye Disease (TED) presents a variety of symptoms, moving from mild to severe and through active and inactive stages. In the early, active phase, patients experience orbital inflammation, eyelid swelling, and redness of the conjunctiva. As the disease progresses to a moderate stage, swelling of the extraocular muscles occurs, leading to double vision (diplopia) and eye pain. Finally, in the severe, fibrotic phase, patients suffer from proptosis (eye bulging) and vision loss due to optic neuropathy.^{1 10}

Pathophysiology of TED: immune-mediated mechanisms

Imagine your body's defence system, like a security team, accidentally attacking the area around your eyes, causing Thyroid Eye Disease (TED). It's like a friendly fire incident. This often starts when the security team is already confused and attacks the thyroid gland in Graves' disease. Think of the thyroid-stimulating hormone receptor (TSHR) as a "communication antenna" on both the thyroid gland and the eye socket's "construction workers" (fibroblasts). In Graves' disease, the immune system sends out "rogue signals" (autoantibodies) that jam the antenna. These signals not only make the thyroid overwork but also confuse the eye socket's construction workers, telling them to build too much. ^{6 8}

These orbital fibroblasts are like "construction workers" in the eye socket. Normally, they maintain the area. But when the "rogue signals" hit their "antennas" (TSHR and IGF-1R), they go haywire. They start building extra "storage units" (adipocytes/fat cells) and "reinforcing beams" (myofibroblasts/scar tissue), causing the eye socket to expand. They also act like "alarm systems," releasing "chemical messengers" (cytokines) that call in more "security guards" (immune cells).^{1 6 12}

The "security guards" (immune cells) are like an overzealous police force. Some, like the "riot police" (Th1 cells), use "tear gas" (IFN-γ, IL-2) to create inflammation. Others, like the "arson squad" (Th17 cells), cause "long-term damage" (IL-17, IL-23). The "detectives" (macrophages) and "weapon manufacturers" (B cells) create more "rogue signals" (autoantibodies) and "chemical messengers" (cytokines), fueling the chaos and keeping the attack going.^{6 11 13}

Finally, hyaluronan is like a "sponge" that soaks up water. When the "construction workers" (fibroblasts) are overactive, they fill the eye socket with too many "sponges." This causes the area to swell, like a waterlogged sponge, increasing pressure and pushing the eye outward. The "reinforcing beams" (fibrosis) also create a stiff, unyielding structure, like concrete, which can compress the optic nerve, possibly leading to vision loss. So, in TED, the body's security team, construction workers, and even sponges all contribute to a chaotic and damaging situation in the eye socket.^{6 11 14}

Clinical implications & disease progression

Thyroid Eye Disease (TED) progresses through distinct phases, each with its clinical implications. During the active, or inflammatory, phase, which typically lasts 6-24 months, immune cells infiltrate and inflame the orbital tissues. This results in symptoms such as eyelid retraction, conjunctival redness, pain, and swelling. Physicians treat this active phase with immunosuppression, using steroids or biologics.^{6 7}

Following the active phase, the condition enters the chronic, or fibrotic, phase. In this stage, the orbital tissues undergo remodelling and fibrosis. Patients experience permanent proptosis (eye bulging), diplopia (double vision), and potentially optic neuropathy. To address these issues, surgeons perform interventions like orbital decompression or strabismus surgery.⁴

Severe TED significantly impacts both vision and quality of life. Compressive optic neuropathy, a severe complication, can cause irreversible vision loss. Furthermore, the cosmetic changes associated with TED, such as proptosis and lid retraction, negatively affect patients' mental health and social interactions.

Potential therapeutic targets & future directions

Doctors currently use several methods to treat Thyroid Eye Disease (TED). Glucocorticoids, or steroids, reduce inflammation during the active phase of the disease. They use orbital radiation therapy in moderate to severe cases. Surgeons perform orbital decompression to treat cases that threaten vision ^{1 2 9}

Researchers are developing new targeted therapies. Teprotumumab, an IGF-1R inhibitor, blocks both IGF-1R and TSHR signalling, which reduces inflammation and eye bulging. The FDA has approved this medication for moderate to severe TED. Additionally, researchers are experimenting with other therapies, such as anti-IL-6 drugs like Tocilizumab, which target inflammation, and JAK inhibitors, which block inflammatory pathways ^{1 2}

Future research aims to identify early biomarkers that indicate TED progression. Scientists are also working on personalised medicine approaches, which would tailor treatments based on an individual's genetic and immune profile.^{2 3}

Conclusion

The body's immune system causes Thyroid Eye Disease (TED), a complicated condition, by inflaming the tissues around the eyes. Autoantibodies, orbital fibroblasts, and immune cells communicate with each other, which results in the progressive reshaping of tissue and damage to vision.

Doctors must diagnose TED early and use targeted therapies to prevent damage that cannot be reversed. Recent improvements in biologic therapies, like Teprotumumab and JAK inhibitors, give hope for better control of the disease. However, researchers need to conduct more studies to improve personalised medicine for people with TED.